Filing Flows › Companies › SBC Medical Group Holdings › Analysis traps
SBC Medical Group Holdings (SBC): analysis traps
Where its figures could mislead a reader, and what to check before taking them at face value · Data: Q2 2026, to Jun 30, 2026, filed Aug 13, 2026; rules v1.1
SBC Medical Group Holdings (SBC): 1 rule of 10 triggered on the filings to Jun 30, 2026: FCF growth = the business improved; 3 with insufficient data; 2 not applicable. Each is a question to verify, with the normal explanation that would produce the same figures.
Check these first
FCF growth = the business improved Triggered · severity medium · confidence medium
Free cash flow rose $5M (+29%), from $18M to $23M, but working capital released $2M more cash than the year before and capital expenditure fell by $1M: 59% of the increase came from sources that need not repeat. Operating cash flow before working capital rose by $2M.
Innocent reading: An expansion programme finished, so capex fell back to maintenance levels for good.
Every rule
A01 FCF growth = the business improved Triggered severity medium · confidence medium
Free cash flow rose $5M (+29%), from $18M to $23M, but working capital released $2M more cash than the year before and capital expenditure fell by $1M: 59% of the increase came from sources that need not repeat. Operating cash flow before working capital rose by $2M.
The figures and how they are read
| Fiscal year before | FY2024 |
| Fiscal year | FY2025 |
| Operating cash flow, year before | $21M |
| Operating cash flow | $25M |
| Capex, year before | $3M |
| Capex | $1M |
| Free cash flow, year before | $18M |
| Free cash flow | $23M |
| Change in FCF | $5M |
| Change in capex | −$1M |
| Working capital: change in its cash contribution | $2M |
| Of which: capex cut | $1M |
| Of which: working capital released | $2M |
| Share of the increase that need not repeat | +59.4% |
| Operating cash flow before working capital: change | 2131430.00 |
FCF = operating cash flow − cash capex; ΔFCF = ΔOCF − ΔCapEx; the working-capital part is the change in the cash-bridge items (receivables, inventory, payables, accruals), with the sign of the cash flow statement
Source: FY2025 (cash flow statement, fiscal year) · FY2024 (cash flow statement, fiscal year before)
What would explain it innocently
- An expansion programme finished, so capex fell back to maintenance levels for good
- Suppliers agreed longer payment terms in a contract
- Inventory was brought down after a glut and will stay down
What to look for in the filing
- Maintenance capex (what it costs to keep the assets working)
- Supplier payment terms and any supply-chain financing
- Management's capex guidance for next year
What would show the trap does not apply
- Next year's FCF holds or rises with capex back at its earlier level and working capital no longer releasing cash
- The 10-K's capex guidance and the segment capex show the cut is a completed programme, not deferral
- The working-capital release matches a disclosed change in terms or a divestiture, not stretched payables or a collection push
Look again: next filing.
A07 Stock compensation added back = no economic cost Not triggered confidence high
Stock compensation is 0.0% of revenue: small enough that adding it back changes little.
The figures and how they are read
| Fiscal year | FY2025 |
| Stock compensation | 0 |
| Revenue | $174M |
| SBC / revenue | +0.0% |
| Buybacks | $5M |
| Buybacks / SBC | — |
| Diluted shares, year before | 96.6M shares |
| Diluted shares | 103.0M shares |
| Diluted shares: change | +6.7% |
SBC / revenue from the cash flow statement's add-back; the diluted weighted share count year over year; buybacks from the financing section
Source: FY2025 (stock compensation, buybacks and the diluted share count, fiscal year)
B02 Receivables growing = future cash is certain Insufficient data
fewer than five quarters with receivables and revenue on file (a year-over-year comparison needs five)
B08 Adjusted profit = economic profit Not triggered confidence low
Adjusted and GAAP EPS were within 10% of each other in the last 3 quarters.
The figures and how they are read
| Quarter / adjusted EPS / GAAP EPS / gap | 2025-09-30 / 0.12 / 0.12 / 0.0; 2026-03-31 / 0.11 / 0.11 / 0.0; 2026-06-30 / 0.1 / 0.1 / 0.0 |
| Quarters with adjusted ≥ 10% above GAAP | 0 |
| Quarters compared | 3 |
| Latest gap | +0.0% |
the analysts' 'actual' (usually the company's adjusted EPS) against GAAP net income ÷ diluted shares for the matching quarter; a gap of 10% or more counts (the stand-in until three releases' reconciliation tables are on file)
Source: 2025-09-30 (adjusted 0.12 vs GAAP 0.12) · 2026-03-31 (adjusted 0.11 vs GAAP 0.11) · 2026-06-30 (adjusted 0.10 vs GAAP 0.10)
C02 Low net debt = no refinancing risk Not triggered confidence medium
$9M comes due within a year, 27.1× covered by cash and investments of $185M plus $62M of free cash flow.
The figures and how they are read
| Cash and investments | $185M |
| Debt | $38M |
| Net debt | −$147M |
| Due within a year | $9M |
| Read from | the debt maturity table |
| Free cash flow, twelve months | $62M |
| Cash plus free cash flow | $246M |
| Coverage of what is due | 27.1 |
| Due in the second year | $14M |
| Balance sheet date | 2026-06-30 |
due within a year from the maturity table (else the current portion of debt), against cash and investments plus free cash flow over the last twelve months (zero if negative); no credit lines assumed
Source: FY2025 (debt maturities, cash and investments)
D03 EPS growth = profit growth Not triggered confidence high
EPS rose 333% and net income rose 335% in Q2 2026; the share count fell 0.9%: EPS growth follows profit growth.
The figures and how they are read
| Quarter | Q2 2026 |
| Quarter before | Q2 2025 |
| EPS, year before | $0.02 |
| EPS | $0.10 |
| Net income, year before | $2M |
| Net income | $11M |
| Diluted shares, year before | 103.5M shares |
| Diluted shares | 102.6M shares |
| EPS growth | +333.3% |
| Net income growth | +335.0% |
| Diluted shares: change | -0.9% |
| eps from profit | $0.08 |
| eps from share count | $0.00 |
EPS and net income against the same quarter a year earlier; the EPS bridge attributes the change to profit first, then to the share count (the order is fixed and disclosed)
Source: Q2 2026 (net income, diluted shares, EPS) · Q2 2025 (the same quarter a year earlier)
E02 Low P/E at a cyclical peak = undervalued Insufficient data
no market value or trailing net income in the valuation research
E07 A precise DCF value = the true value Insufficient data
no DCF in the valuation research for this company
J06 A bank's low P/E and high profit = safe Not applicable
not a bank
J08 A REIT's low net income = the dividend is unsafe Not applicable
not a REIT
What the statuses mean
Triggered: the filings show the pattern; read the normal explanations and the missing evidence before concluding anything. To review: one quarter or a weak signal; a reader's judgement, not a pattern. Not triggered: the pattern is absent on these figures. Insufficient data: the filings read so far do not hold what the rule needs; this is not a clean bill. Not applicable: the rule is not meant for this kind of company (a bank's working capital, a loss-making quarter's EPS growth). Out of date: the latest filing is more than fifteen months old.
Severity is what the pattern could mean for cash, value or solvency; confidence is how reliable the inputs and the reading are. The two are kept apart.
Record a view
A reader's judgement, grounds, what would change it and the next review; kept in the browser (needs JavaScript).
Every rule and the companies it triggers on → SBC Medical Group Holdings: cash flow →
Each rule reads the company's own filings by a fixed formula and says what would explain the same figures innocently. A triggered rule is a question to verify, not a finding of manipulation, and not a view on the stock. Missing data is shown as missing, never as clear. Not investment advice.